$PALI
PALISADE BIO, INC.

2022 Q1 Form 10-Q Financial Statement

#000095017022009812 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.929M $1.720M
YoY Change 70.29% 32.31%
% of Gross Profit
Research & Development $959.0K $471.1K
YoY Change 103.56% -32.4%
% of Gross Profit
Depreciation & Amortization $1.000K $10.00K
YoY Change -90.0% -66.67%
% of Gross Profit
Operating Expenses $3.888M $1.954M
YoY Change 98.98% -2.13%
Operating Profit -$3.888M -$1.954M
YoY Change 98.98% -1.83%
Interest Expense $1.000K $1.711M
YoY Change -99.94% 66243.54%
% of Operating Profit
Other Income/Expense, Net -$317.0K -$2.076M
YoY Change -84.73% -62.83%
Pretax Income -$4.205M -$2.290M
YoY Change 83.62% -69.79%
Income Tax
% Of Pretax Income
Net Earnings -$4.205M -$4.030M
YoY Change 4.34% 69.04%
Net Earnings / Revenue
Basic Earnings Per Share -$12.96
Diluted Earnings Per Share -$259.2K -$792.4K
COMMON SHARES
Basic Shares Outstanding 18.23M 17.30M
Diluted Shares Outstanding 324.5K

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.644M $6.560M
YoY Change 1.28% -34.6%
Cash & Equivalents $6.600M $615.0K
Short-Term Investments
Other Short-Term Assets $1.528M $2.170M
YoY Change -29.59% 429.27%
Inventory
Prepaid Expenses $1.309M
Receivables $25.26K
Other Receivables $0.00
Total Short-Term Assets $8.258M $8.756M
YoY Change -5.68% -16.32%
LONG-TERM ASSETS
Property, Plant & Equipment $2.000K $7.243K
YoY Change -72.39% -76.73%
Goodwill
YoY Change
Intangibles $141.6K
YoY Change -78.2%
Long-Term Investments
YoY Change
Other Assets $26.00K $10.00K
YoY Change 160.0% -66.67%
Total Long-Term Assets $92.00K $159.3K
YoY Change -42.26% -82.23%
TOTAL ASSETS
Total Short-Term Assets $8.258M $8.756M
Total Long-Term Assets $92.00K $159.3K
Total Assets $8.350M $8.915M
YoY Change -6.34% -21.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.147M $520.0K
YoY Change 120.58% -45.83%
Accrued Expenses $580.0K $320.0K
YoY Change 81.25% 146.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.864M $1.015M
YoY Change 83.66% -14.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.694M $170.0K
YoY Change 896.47% -15.0%
Total Long-Term Liabilities $1.694M $170.0K
YoY Change 896.47% -15.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.864M $1.015M
Total Long-Term Liabilities $1.694M $170.0K
Total Liabilities $3.558M $1.186M
YoY Change 199.97% -14.21%
SHAREHOLDERS EQUITY
Retained Earnings $98.80M -$240.5M
YoY Change -141.08% 4.78%
Common Stock $183.0K $28.83K
YoY Change 534.84% -69.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.792M -$20.06M
YoY Change
Total Liabilities & Shareholders Equity $8.350M $8.915M
YoY Change -6.34% -21.53%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$4.205M -$4.030M
YoY Change 4.34% 69.04%
Depreciation, Depletion And Amortization $1.000K $10.00K
YoY Change -90.0% -66.67%
Cash From Operating Activities -$3.764M -$1.250M
YoY Change 201.12% -25.49%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -87.00K 1.152M
YoY Change -107.55% -82.53%
NET CHANGE
Cash From Operating Activities -3.764M -1.250M
Cash From Investing Activities 0.000
Cash From Financing Activities -87.00K 1.152M
Net Change In Cash -3.851M -98.00K
YoY Change 3829.59% -101.99%
FREE CASH FLOW
Cash From Operating Activities -$3.764M -$1.250M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
5800 Armada Drive, Suite 210
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-33672
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
704-4900
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
PALI
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21880169
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6644000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10495000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1614000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
8258000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
12374000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
64000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2022Q1 us-gaap Assets
Assets
8350000
CY2021Q4 us-gaap Assets
Assets
12512000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1147000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1323000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
580000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
72000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
511000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
65000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
112000
CY2022Q1 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
0
CY2021Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
87000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1864000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2496000
CY2022Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1694000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2651000
CY2022Q1 us-gaap Liabilities
Liabilities
3558000
CY2021Q4 us-gaap Liabilities
Liabilities
5147000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18233479
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18233479
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14239177
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14239177
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
183000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
103454000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
101862000
CY2022Q1 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-98847000
CY2021Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-94642000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4792000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8350000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12512000
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
959000
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
692000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2929000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1262000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
3888000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1954000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3888000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1954000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022Q1 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021Q1 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
793000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
42000
CY2022Q1 us-gaap Interest Expense
InterestExpense
1000
CY2021Q1 us-gaap Interest Expense
InterestExpense
1711000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
CY2022Q1 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
CY2021Q1 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-317000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2076000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4030000
CY2022Q1 pali Income Loss Per Share Basic And Diluted
IncomeLossPerShareBasicAndDiluted
-0.26
CY2021Q1 pali Income Loss Per Share Basic And Diluted
IncomeLossPerShareBasicAndDiluted
-1.45
CY2022Q1 pali Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
16223656
CY2021Q1 pali Weighted Average Shares Outstanding Basic And Diluted
WeightedAverageSharesOutstandingBasicAndDiluted
2774502
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
358000
CY2022Q1 pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1274000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
4792000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-16602000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4030000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
569000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-20063000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4205000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4030000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
CY2022Q1 pali Noncash Lease Expense
NoncashLeaseExpense
45000
CY2021Q1 pali Noncash Lease Expense
NoncashLeaseExpense
39000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
279000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
0
CY2021Q1 us-gaap Accretion Expense
AccretionExpense
1590000
CY2022Q1 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
0
CY2021Q1 pali Loss On Issuance Of Secured Debt
LossOnIssuanceOfSecuredDebt
686000
CY2022Q1 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
CY2021Q1 pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
CY2022Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
793000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
42000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
358000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
569000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-59000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-265000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-21000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-59000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
183000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-439000
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-47000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-39000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3764000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6644000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
615000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1250000
CY2022Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
87000
CY2021Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
11000
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
CY2021Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1250000
CY2022Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
CY2021Q1 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
87000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-87000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1152000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3851000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-98000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
739000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6670000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
641000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6670000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
641000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
3000
CY2022Q1 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
CY2021Q1 pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
CY2022Q1 pali Deferred Equity Issuance Costs In Accounts Payable And Accrued Liabilities
DeferredEquityIssuanceCostsInAccountsPayableAndAccruedLiabilities
82000
CY2021Q1 pali Deferred Equity Issuance Costs In Accounts Payable And Accrued Liabilities
DeferredEquityIssuanceCostsInAccountsPayableAndAccruedLiabilities
41000
CY2022Q1 pali Deferred Transaction Costs In Accounts Payable And Accrued Liabilities
DeferredTransactionCostsInAccountsPayableAndAccruedLiabilities
0
CY2021Q1 pali Deferred Transaction Costs In Accounts Payable And Accrued Liabilities
DeferredTransactionCostsInAccountsPayableAndAccruedLiabilities
2337000
CY2022Q1 pali Debt Issuance Costs Included In Accounts Payable
DebtIssuanceCostsIncludedInAccountsPayable
0
CY2021Q1 pali Debt Issuance Costs Included In Accounts Payable
DebtIssuanceCostsIncludedInAccountsPayable
16000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
98800000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6600000
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.55
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to clinical trial accruals and the valuation of derivative liabilities and stock-based compensation instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100000000
CY2022Q1 us-gaap Deferred Costs Current
DeferredCostsCurrent
82000000
CY2021Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
0
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span></p>
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
5.96
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5347517
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7181741000
CY2021Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
7181741
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7810451
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1422450
CY2022Q1 pali Accrued Accounts Payable
AccruedAccountsPayable
399000
CY2021Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
195000
CY2022Q1 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
69000
CY2021Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
158000
CY2022Q1 pali Accrued Director Stipends
AccruedDirectorStipends
112000
CY2021Q4 pali Accrued Director Stipends
AccruedDirectorStipends
110000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
580000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
463000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1120000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1408000
CY2022Q1 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
86000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
150000
CY2022Q1 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
210000
CY2021Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
215000
CY2022Q1 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
90000
CY2021Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
78000
CY2022Q1 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
26000
CY2021Q4 pali Prepaid Expenses And Other Current Assets Deposits
PrepaidExpensesAndOtherCurrentAssetsDeposits
26000
CY2022Q1 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
82000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
0
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1614000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1879000
CY2021Q3 us-gaap Warrants And Rights Outstanding Measurement Input
WarrantsAndRightsOutstandingMeasurementInput
3900000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1956855
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.32
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y4M13D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y5M12D
CY2022Q1 pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
2250000
CY2022Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
1.10
CY2022Q1 pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P5Y3M29D
CY2022Q1 pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
-3994302
CY2022Q1 pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
3.88
CY2022Q1 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
-89922
CY2022Q1 pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
80.72
CY2022Q1 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
5347517
CY2022Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
4.20
CY2022Q1 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y7M20D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.97
CY2022Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
CY2022Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0185
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
499600
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.97
CY2022Q1 pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y10M9D
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2456455
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.03
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2456455
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.03
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
43000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
946865
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.60
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y9M7D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.63
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
400000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
358000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
569000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1900000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M17D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000.0
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
CY2022Q1 pali Milestone Payments
MilestonePayments
0
CY2021Q1 pali Milestone Payments
MilestonePayments
0
CY2022Q1 us-gaap Lease Cost
LeaseCost
49000
CY2021Q1 us-gaap Lease Cost
LeaseCost
49000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y4M24D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2022Q1 pali Operating Leases Future Minimum Payments
OperatingLeasesFutureMinimumPayments
67000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2000
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
377474
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.45
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2022Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
112500
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
110000

Files In Submission

Name View Source Status
0000950170-22-009812-index-headers.html Edgar Link pending
0000950170-22-009812-index.html Edgar Link pending
0000950170-22-009812.txt Edgar Link pending
0000950170-22-009812-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img194420022_0.jpg Edgar Link pending
img60043614_0.jpg Edgar Link pending
img60043614_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20220331.htm Edgar Link pending
pali-20220331.xsd Edgar Link pending
pali-20220331_cal.xml Edgar Link unprocessable
pali-20220331_def.xml Edgar Link unprocessable
pali-20220331_htm.xml Edgar Link completed
pali-20220331_lab.xml Edgar Link unprocessable
pali-20220331_pre.xml Edgar Link unprocessable
pali-ex10_1.htm Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending